期刊文献+

5-Aza-dc对膀胱癌ScaBer细胞CDH13基因甲基化状态和蛋白表达以及细胞增殖迁移侵袭的影响 被引量:3

The influence of 5-Aza-dc on the methylation status and protein expression of CDH13 as well as cell proliferation, migration and invasion of bladder cancer ScaBer cell
原文传递
导出
摘要 目的 探讨去甲基化药物5-Aza-dc对膀胱癌ScaBer细胞CDH13基因甲基化状态和蛋白表达以及细胞增殖迁移侵袭的影响.方法 以膀胱癌ScaBer细胞为研究对象,分为5-Aza-dc处理组和对照组.应用5-Aza-dc与ScaBer细胞共同孵育后,用MSP检测CDH13基因甲基化状态、western blot检测CDH13的表达水平、MTT法检测细胞增殖、划痕实验检测细胞迁移能力、Transwell法检测细胞侵袭能力.结果 5-Aza-dc与ScaBer细胞共同孵育后CDH13基因甲基化状态得到逆转,与对照组相比CDH13蛋白表达明显增加(P< 0.05);实验组细胞增殖能力下降,迁移和侵袭能力减弱,与对照组相比差异均有统计学意义(P<0.05).结论 5-Aza-dc可逆转CDH13基因的甲基化状态并使其蛋白表达增加,CDH13表达增加后细胞的增殖、迁移和侵袭能力明显减弱,CDH13有可能成为膀胱癌治疗的新的靶点. Objectives The purpose of this study was to investigate the influence of 5-Aza-dc on the methylation status and protein expression of CDH13 gene in bladder cancer ScaBer cell,as well as on the proliferation,migration and invasion capability.Methods Bladder cancer ScaBer cells was investigated in this study,and divided into 5-Aza-dc treatment group and control group.MSP was used to detect the methylation status of CDH13 gene; western blot was used to detect the protein expression of CDH13,MMT was used to detect cell proliferation,scratch assay was used to detect cell migration and transwell assay was used to detect cell invasion capability.Results The methylation status of CDH13 gene in bladder cancer ScaBer cell was reversed after the treatment of 5-Aza-dc and the protein expression of CDH13 was increased significantly(P 〈 0.05).The cell proliferation,migration and invasion capability was diminished after the treatment of 5-Aza-dc,and the difference was statistically significant compared to control group(P 〈 0.05).Conclusions The methylation status of CDH13 gene can be reversed after the treatment of 5-Aza-dc and the CDH13 protein expression was increased after the reversion of the methylation status of CDH13 gene.The cell proliferation,migration and invasion capability was decreased significantly after the increasing of CDH13 protein expression,and CDH13 gene may be a novel treatment target for bladder cancer.
出处 《国际泌尿系统杂志》 2015年第1期4-8,共5页 International Journal of Urology and Nephrology
基金 江苏大学医学临床科技发展基金项目(编号:JLY201220077) 徐州市医学青年后备人才项日(编号:2014007)
关键词 膀胱肿瘤 基因 甲基化 细胞增殖 Urinary Bladder Neoplasms Genes Methylation Cell Proliferation
  • 相关文献

参考文献24

  • 1Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world [ J ]. World J Urol, 2009, 27 (3) :289 -293.
  • 2Andreeva AV, Kutuzov MA. Cadherin 13 in cancer[J]. Genes Chromosomes Cancer, 2010, 49 (9) :775 - 790.
  • 3Lin YL, He ZK, Li ZG, et at. Downregnlation of CDH13 expres- sion promotes invasiveness of bladder transitional cell carcinoma [J]. Urol Int, 2013, 90(2) :225 -232.
  • 4Lin YL, Sun G, Liu XQ, et al. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma[ J]. J Int Med Res, 2011, 39 (1) :179 - 186.
  • 5Lin YL, Liu XQ, Li WP, et at. Promoter methylation of H - cad- herin is a potential biomarker in patients with bladder transitional cell carcinoma [ J ]. Int Urol Nephrol, 2012, 44 ( 1 ) : 111 - 117.
  • 6Chihara Y, Kanai Y, Fujimoto H, et al. Diagnostic markers of urothelial cancer based on DNA methylation analysis [ J ]. BMC Cancer,2013,13:275.
  • 7Li H, Wang J, Xiao W, et al. Epigenetic inactivation of i(LF4 is associated with urothelial cancer progression and early recurrence [J].J Urol, 2014, 191(2) :493 -501.
  • 8Dudziec E, Goepel jR Catto JW. Globai epigenetic profiling in bladder cancer[ J]. Epigenomics, 2011, 3 ( 1 ) :35 -45.
  • 9van der Heijden AG. The role of methylation in urological tumours [J]. Arch Esp Urol, 2013, 66(5):432 -439.
  • 10Kandimalla R, van Tilborg AA, Zwarthoff EC. DNA methylation -based biomarkers in bladder cancer[ J]. Nat Rev Urol, 2013, 10(6) :327 -335.

二级参考文献35

  • 1Kiltie AE. Common predisposition alleles for moderately common cancers: bladder cancer. Curr Opin Genet Dev, 2010, 20 (3) : 218 -224.
  • 2Volanis D, Kadiyska T, Galanis A, et al. Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett, 2010,193(2) :131-137.
  • 3Diaz De St? hi T, Segersten U, Malmstr? m PU. Molecular ge?netics of bladder cancer: an update. Minerva Urol Nefrol, 2008, 60(4) :205 -216.
  • 4Marzese DM, Gago FE, OrozcoJO, et al. Aberrant DNA methyla?tion of cancer - related genes in giant breast fibroadenoma: a case report.J Med Case Reports, 2011,5(1) :516.
  • 5Caffarelli E, Filetici P. Epigenetic regulation in cancer develop?ment. Front Biosci, 2011, 17 :2682 -2694.
  • 6Sceusi EL, Loose DS, Wray CJ. Clinical implications of DNA methylation in hepatocellular carcinoma. HPB (Oxford), 2011, 13(6) :369 -376.
  • 7Rasoulpour RJ, LeBaron MJ, Ellis - Hutchings RG, et al. Epige?netic screening in product safety assessment: are we there yet. Toxicol Mech Methods, 2011, 21 (4) :298 - 311.
  • 8Khandige S, Shanbhogue VV, Chakrabarty S, et a!. Methylation markers: a potential force driving cancer diagnostics forward. On?col Res, 2011,19(3 -4) :105 -110.
  • 9Ongenaert M, Van Neste L, De Meyer T, Menschaert G, et al. PubMeth: a cancer methylation database combining text - mining and expert annotation. Nucleic Acids Res, 2008, 36 :842 - 846.
  • 10TsouJA, GallerJS, Siegmund KD, et a!. Identification of a pan?el of sensitive and specific DNA methylation markers for lung ade?nocarcinoma. Mol Cancer, 2007 , 6: 70 - 83.

共引文献11

同被引文献5

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部